Stocks / NASDAQ / ContraVir Pharmaceuticals Inc

ContraVir Pharmaceuticals Inc

Our Opinion

ContraVir Pharmaceuticals Inc is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.

Supporting Evidence:

Preclinical study data of ContraVir’s CRV431

“CRV431 reduced liver HBV DNA in a transgenic mouse model of viral replication without significant toxicity. Further animal studies confirmed a strong safety profile for CRV431, and highlighted the ability of CRV431 to reduce liver damage, preventing the development of fibrosis by ~55% in a mouse model of NASH (nonalcoholic steatohepatitis).”

Company Description

ContraVir Pharmaceuticals, Inc. is a development stage biopharmaceutical company which is focused primarily on the development of drugs to treat herpes zoster or shingles. The company currently developing a compound called FV-100 for the treatment of shingles. It is also developing CMX157, a potent analog of the successful antiviral drug tenofovir DF. ContraVir Pharmaceuticals was founded on May 15, 2013 and is headquartered in Edison, NJ. [Source: MarketWatch]

Company Website: